IMCR

Immunocore Holdings plc ADR (IMCR) | Rumor.io

Immunocore Holdings

IMCR

Attention (50-day avg)0%

Attention rank (50-day avg)#2,743

Bullish sentiment (50-day avg)100%

Price to earnings ratio-43.2

Market capitalization1.6B

Earnings per share-0.36

Dividend yield (TTM)—

Revenue (annual)400M

Net income (annual)-35.5M

Social

What share of all stock conversation is about IMCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 31

Immunocore's brenetafusp continues to show promising clinical activity in late-line cutaneous melanoma patients.
Immunocore reports updated Phase 1 data of brenetafusp at ASCO 2024, showing potential for improved outcomes in immune checkpoint pre-treated cutaneous melanoma patients.
Top analyst price target for Immunocore is expected to be announced next week, potentially driving the stock price.

Generated by AI

Sentiment

Of the messages about IMCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	93.68% +8.48
Bearish	—	—	0% 0	6.32% -8.48

Topics

Of the messages about IMCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	86.18%
Analysts	—	—	0%	12.96%
Controversies	—	—	0%	0.57%
Earnings	—	—	0%	0.28%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Sep 9

Immunocore Holdings plc presented promising initial Phase 1 data for its first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress.
The therapy demonstrated T cell activation and tolerance in a dose-escalation study, with potential for treating various diseases, including infectious diseases.
Immunocore's shares plummeted 22% after the presentation, but the company has an approved transaction with positive OS and PFS data, indicating a platform approach beyond oncology.

Generated by AI

Community

Of the messages about IMCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	73.08%	73.69%
Newcomers	—	—	26.92%	26.31%

Regulars· Feb 14

Regulars are selling IMCR, with one participant breaking even and another selling at highs due to market environment.
IMCR's chart is being compared to KITE before its acquisition by GILD, suggesting a potential trend reversal.
IMCR's revenue growth rate is exceptionally high at 595.50%, ranking 67th among 5738 companies in the database.

Newcomers· Sep 9

Newcomers are focused on Immunocore's approved Tx, highlighting its OS and PFS as positive aspects in the TCR space.
The data presented by Immunocore for its uveal melanoma drug is deemed "pretty meh" with a mention of the company's use of Soluble TCE and its effect on patients' endogenous T cells.
Immunocore's stock price plummeted 22% after presenting its phase 1 data for TCR therapy targeting PRAME, with one user noting they had switched from GSK to IMCR about a dozen days prior.

Generated by AI

News

Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial (NASDAQ:IMCR)

21h agoSeeking Alpha

Immunocore: KIMMTRAK Nearly Covers The Valuation Before A Major Phase 3 Readout (NASDAQ:IMCR)

5d agoSeeking Alpha

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

IMCR achieves target enrollment in the phase III TEBE-AM study investigating Kimmtrak in previously treated patients with advanced melanoma.

14d agoYahoo Finance

Immunocore at Morgan Stanley conference: kimmtrak drives growth

15d agoInvesting.com

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as early as end of 2026 (OXFORDSHIRE, England & CONSHOHOCKEN, PA & ROCKVILLE, MD, US, 14 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve

16d agoYahoo Finance

Immunocore Completes Enrollment in Study of Potential Advanced Melanoma Treatment

Immunocore (IMCR) achieved its target enrollment of 540 patients in a phase 3 clinical trial evaluat

16d agoYahoo Finance

Also Discussed

Investors talking about IMCR also mention

#	Name	Attention
1	Immatics N.V.IMTX	0%0
2	BPMC - Blueprint Medicines Corporation	——
3	IDEAYA Biosciences Inc.IDYA	0%-0.01
4	WisdomTree 1-3 Year Laddered Treasury FundUSSH	0%0
5	First Trust Multi-Asset Diversified Income Index FundMDIV	0%0
6	F/m 10-Year Investment Grade Corporate Bond ETFZTEN	0%0
7	SWTX - SpringWorks Therapeutics, Inc.	——
8	DAWN - Day One Biopharmaceuticals, Inc.	——
9	Mirum Pharmaceuticals, Inc.MIRM	0%0
10	AFMD - Affimed N.V.	——

Immunocore Holdings plc ADR

Healthcare
Biotechnology

Immunocore Holdings plc ADR is a commercial-stage biotechnology company focused on developing T cell receptor-based immunotherapies designed to help the immune system recognize and eliminate diseased cells. Immunocore’s lead marketed product, KIMMTRAK, is used to treat unresectable or metastatic uveal melanoma, while its broader platform supports research and development across oncology, infectious diseases, and autoimmune disorders. The company’s ImmTAX technology underpins a portfolio of current and investigational therapies aimed at harnessing or redirecting immune responses with precision. Immunocore serves patients and healthcare providers through specialized therapies that address serious, hard-to-treat conditions, and its programs span clinical development as well as commercial operations in key international markets. Headquartered in Abingdon, United Kingdom, Immunocore Holdings plc ADR remains a notable participant in the biotechnology sector through its focus on novel immune-based medicines.

Website

Location

92 Park Drive

Abingdon, OX14 4RY

United Kingdom

Social

What share of all stock conversation is about IMCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

May 31

Immunocore's brenetafusp continues to show promising clinical activity in late-line cutaneous melanoma patients.
Immunocore reports updated Phase 1 data of brenetafusp at ASCO 2024, showing potential for improved outcomes in immune checkpoint pre-treated cutaneous melanoma patients.
Top analyst price target for Immunocore is expected to be announced next week, potentially driving the stock price.

Generated by AI

Sentiment

Of the messages about IMCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	93.68% +8.48
Bearish	—	—	0% 0	6.32% -8.48

Topics

Of the messages about IMCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	86.18%
Analysts	—	—	0%	12.96%
Controversies	—	—	0%	0.57%
Earnings	—	—	0%	0.28%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	0%

Sep 9

Immunocore Holdings plc presented promising initial Phase 1 data for its first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress.
The therapy demonstrated T cell activation and tolerance in a dose-escalation study, with potential for treating various diseases, including infectious diseases.
Immunocore's shares plummeted 22% after the presentation, but the company has an approved transaction with positive OS and PFS data, indicating a platform approach beyond oncology.

Generated by AI

Community

Of the messages about IMCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	73.08%	73.69%
Newcomers	—	—	26.92%	26.31%

Regulars· Feb 14

Regulars are selling IMCR, with one participant breaking even and another selling at highs due to market environment.
IMCR's chart is being compared to KITE before its acquisition by GILD, suggesting a potential trend reversal.
IMCR's revenue growth rate is exceptionally high at 595.50%, ranking 67th among 5738 companies in the database.

Newcomers· Sep 9

Newcomers are focused on Immunocore's approved Tx, highlighting its OS and PFS as positive aspects in the TCR space.
The data presented by Immunocore for its uveal melanoma drug is deemed "pretty meh" with a mention of the company's use of Soluble TCE and its effect on patients' endogenous T cells.
Immunocore's stock price plummeted 22% after presenting its phase 1 data for TCR therapy targeting PRAME, with one user noting they had switched from GSK to IMCR about a dozen days prior.

Generated by AI

Immunocore Holdings

Social

May 31

Sep 9

Regulars· Feb 14

Newcomers· Sep 9

Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial (NASDAQ:IMCR)

Immunocore: KIMMTRAK Nearly Covers The Valuation Before A Major Phase 3 Readout (NASDAQ:IMCR)

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

Immunocore at Morgan Stanley conference: kimmtrak drives growth

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore Completes Enrollment in Study of Potential Advanced Melanoma Treatment

Also Discussed

Immunocore Holdings plc ADR

Company Information

Location

Immunocore: Advanced Cutaneous Melanoma Data Catalysts Feel Crucial (NASDAQ:IMCR)

Immunocore: KIMMTRAK Nearly Covers The Valuation Before A Major Phase 3 Readout (NASDAQ:IMCR)

Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study

Immunocore at Morgan Stanley conference: kimmtrak drives growth

Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma

Immunocore Completes Enrollment in Study of Potential Advanced Melanoma Treatment

Also Discussed

Social

May 31

Sep 9

Regulars· Feb 14

Newcomers· Sep 9